5-HT1A receptor antagonist confers neuroprotection against glaucoma, study shows
May 21, 2024
Lowering intraocular pressure (IOP) is still the only approach for treating glaucoma, in which there is mitochondrial damage in the retinal ganglion cells (RGCs). Activating survival pathways in RGCs was thus hypothesized by Indiana University scientists as a strategy for treating glaucoma independently of IOP modulation.